Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ann Pharmacother. 2002 Jan;36(1):93-101.

Rosuvastatin for the treatment of patients with hypercholesterolemia.

Author information

  • 1Medical Cardiology and Lipid Clinic, Cook County Hospital, Department of Pharmacy Practice, University of Illinois at Chicago, IL, USA. cpang@tigger.cc.uic.edu

Abstract

OBJECTIVE:

To review the currently available information on rosuvastatin in the treatment of primary hypercholesterolemia.

DATA SOURCES:

MEDLEY (2000-January 2001), MEDLIT, MEDLINE, EMBASE, SciSearch, Current Contents, Derwent, Drug, BIOSIS, Adis LMS Drug Alerts, and International Pharmaceutical Abstracts (1994-July 2001) were searched; unpublished data obtained from the manufacturer were also included.

STUDY SELECTION:

Studies evaluating rosuvastatin including abstracts, proceedings, and data on file from the manufacturer were considered for inclusion. English-language literature was evaluated for pharmacology, pharmacodynamics, pharmacokinetics, therapeutic use, and adverse effects of rosuvastatin. Additional relevant citations were used in the introductory material and discussion section.

DATA EXTRACTION:

English-language study abstracts selected for inclusion were limited to those on human subjects. Animal data were included only if human data were not available.

DATA SYNTHESIS:

Resuvastatin, a new synthetic hydroxymethylglutaryl coenzyme A reductase inhibitor (HMG-CoA RI), recently completed Phase III clinical trials. At a dosage of 1-80 mg/d, the drug significantly reduced total cholesterol and low-density-lipoprotein cholesterol (LDL-C) and produced beneficial effects on other lipid parameters as well. Overall, resuvastatin was well tolerated.

CONCLUSIONS:

In hypercholesterolemic patients, rosuvastatin reduced LDL-C and other lipid parameters to a greater degree than currently available agents. One advantage of rosuvastatin is that it achieves target LDL-C goals in a greater proportion of treated patients with similar adverse events compared with those treated with other HMG-CoA RIs. The potential to reduce risk of coronary heart disease events and decrease mortality as well as cost comparisons with currently used HMG-CoA RIs remains a subject of further investigation.

PMID:
11816268
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk